Compare MSGE & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | AVDL |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | MSGE | AVDL |
|---|---|---|
| Price | $54.14 | $21.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $49.80 | $18.38 |
| AVG Volume (30 Days) | 290.0K | ★ 1.4M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $962,282,000.00 | $248,517,000.00 |
| Revenue This Year | $9.47 | $65.47 |
| Revenue Next Year | $5.43 | $30.88 |
| P/E Ratio | $74.86 | ★ N/A |
| Revenue Growth | 0.68 | ★ 79.88 |
| 52 Week Low | $28.29 | $6.38 |
| 52 Week High | $55.75 | $23.57 |
| Indicator | MSGE | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 59.83 |
| Support Level | $51.36 | $21.50 |
| Resistance Level | $54.70 | $21.60 |
| Average True Range (ATR) | 1.21 | 0.12 |
| MACD | -0.11 | -0.09 |
| Stochastic Oscillator | 63.10 | 63.24 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.